|
October 2, 2019 |
Use of ACE Inhibitors Linked to 24% Drop in Type 2 Diabetes Risk While medications to lower blood pressure might all meet their primary purpose, other factors should come into play, according to a new study. Find out how much taking ACE inhibitors lowers the risk of developing type 2 diabetes compared with placebo in patients taking them. |
|
|
FDA Approves First Oral GLP-1 Treatment for Use in Type 2 Diabetes Pharmacists who deal with needle-phobic patients with type 2 diabetes should applaud the FDA’s approval of the first oral glucagon-like peptide receptor protein treatment. Like the injected versions, however, the new drug still has prescribing information that limits usage in some type 2 diabetes patients. Here is more information. |
|
Sertraline Reduces Anxiety, Not Depression, in First 6 Weeks Pharmacists might be surprised by new information on what happens when patients take sertraline, marketed as Zoloft. Researchers found strong evidence it reduces anxiety in the first 6 weeks, but weaker evidence that it resolves depressive symptoms over 12 weeks. Here are more details. |
|
|
More Evidence of Link Between Antibiotic Use, C Difficile in Hospitals Which antibiotics are most likely to increase the risk of Clostridioides difficile in hospitals and how does their use affect prevalence of the sometimes fatal gastrointestinal illness? A new study looked at the issue, and here is what CDC researchers and colleagues found.
|
|
|
Connect With U.S. Pharmacist
|
|
|
|
|